Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

2,000

Employees2,000

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

2,000

Employees2,000

NBIX Key Statistics

Market cap

15.82B

Market cap15.82B

Price-Earnings ratio

24.36

Price-Earnings ratio24.36

Dividend yield

—

Dividend yield—

Average volume

1.49M

Average volume1.49M

High today

$159.75

High today$159.75

Low today

$156.09

Low today$156.09

Open price

$158.70

Open price$158.70

Volume

1.12M

Volume1.12M

52 Week high

$162.39

52 Week high$162.39

52 Week low

$117.59

52 Week low$117.59

Stock Snapshot

Neurocrine(NBIX) stock is priced at $157.21, giving the company a market capitalization of 15.82B. It carries a P/E multiple of 24.36.

As of 2026-05-19, Neurocrine(NBIX) stock has fluctuated between $156.09 and $159.75. The current price stands at $157.21, placing the stock +0.7% above today's low and -1.6% off the high.

Neurocrine(NBIX) shares are trading with a volume of 1.12M, against a daily average of 1.49M.

During the past year, Neurocrine(NBIX) stock moved between $117.59 at its lowest and $162.39 at its peak.

NBIX News

TipRanks 11h

Neurocrine announces new data from a clinician survey in Ingrezza

Neurocrine (NBIX) Biosciences announced the presentation of new data from a clinician survey highlighting the functional impact experienced by patients with mil...

TipRanks 17h

Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 18h

Neurocrine completes acquisition of Soleno Therapeutics

Neurocrine Biosciences (NBIX) announced the completion of its acquisition of Soleno Therapeutics (SLNO), strengthening the company’s leadership in endocrinology...

Analyst ratings

87%

of 30 ratings

Buy

86.7%

Hold

13.3%

Sell

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

iShares MSCI Emerging Mar…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.